Open in Screener

MLYS

Mineralys Therapeutics Inc

Jun 05 • 04:00PM ET

23.69

-1.36 -5.43 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: CGON KYMR NUVL INCY RYTM APGE KRYS AXSM BMRN NBIX

| Held by: XBI VTI IWM VXF IBB IWO SCHA VTWO VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.06	Insider Own	26.48%	Shs Outstand	82.45M	Perf Week	-24.79%
Market Cap	1.95B	Forward P/E	-	EPS next Y	-2.10	Insider Trans	-0.61%	Shs Float	60.66M	Perf Month	-21.35%
Enterprise Value	1.31B	PEG	-	EPS next Q	-0.55	Inst Own	88.36%	Short Float	14.88%	Perf Quarter	-10.91%
Income	-151.78M	P/S	-	EPS this Y	-0.87%	Inst Trans	1.62%	Short Ratio	6.42	Perf Half Y	-39.57%
Sales	0.00M	P/B	3.06	EPS next Y	9.25%	ROA	-30.12%	Short Interest	9.02M	Perf YTD	-34.72%
Book/sh	7.74	P/C	3.03	EPS next 5Y	20.15%	ROE	-30.98%	52W High	47.65 -50.28%	Perf Year	51.66%
Cash/sh	7.83	P/FCF	-	EPS past 3/5Y	-46.34% -101.68%	ROIC	-23.78%	52W Low	12.59 88.17%	Perf 3Y	62.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.53% 6.00%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	44.87%	Oper. Margin	-	ATR (14)	1.87	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	44.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	33.16	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	44.33	EPS Q/Q	40.19%	SMA20	-16.55%	Beta	0.64	Target Price	49.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-15.37%	Rel Volume	2.93	Prev Close	25.05
Employees	76	LT Debt/Eq	0.00	Earnings	May 06 AMC	SMA200	-27.69%	Avg Volume	1.41M	Price	23.69
IPO	Feb 10, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.47% -	Trades		Volume	4,120,268	Change	-5.43%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-26	Initiated	TD Cowen	Buy
Jun-11-25	Initiated	Jefferies	Hold	$15
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Jun-03-26 06:05AM	Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire) -13.14%
06:00AM	Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing (GlobeNewswire)
May-30-26 11:15AM	Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
May-27-26 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-18-26 04:05PM	Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
08:30PM	Loading…
May-06-26 08:30PM	Mineralys Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
04:05PM	Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-26 05:34PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-29-26 04:05PM	Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 (GlobeNewswire)
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +15.23%
Mar-24-26 08:00AM	Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer (GlobeNewswire)
Mar-16-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 08:30AM	Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-12-26 11:06PM	Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
04:05PM	Loading…
04:05PM	Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-26 04:30PM	Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 (GlobeNewswire)
Feb-26-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-26 07:00PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.45%
Jan-30-26 12:24AM	Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones (Insider Monkey)
Jan-06-26 08:00AM	Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 (GlobeNewswire)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-12-25 11:00AM	Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup (GlobeNewswire)
Dec-05-25 09:55AM	Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet (Zacks)
Nov-26-25 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-25 12:02AM	Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com) +5.87%
Nov-10-25 04:05PM	Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.04%
Nov-07-25 06:10PM	Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
04:05PM	Loading…
Nov-05-25 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.66%
Nov-03-25 08:00AM	Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-17-25 09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Sep-30-25 12:34PM	Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups (Insider Monkey)
08:00AM	Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension (GlobeNewswire)
Sep-29-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-16-25 05:41PM	It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps (Motley Fool)
Sep-09-25 12:00PM	What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? (Zacks) +7.15%
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-05-25 09:00AM	Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need (GlobeNewswire) +5.07%
Sep-04-25 04:01PM	Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.23%
Sep-03-25 11:13AM	Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak (Insider Monkey)
Sep-02-25 09:33PM	Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +86.43%
04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:05PM	Why Mineralys Nearly Doubled On AstraZeneca's Hypertension Results (Investor's Business Daily)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-30-25 10:15AM	AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results (Investor's Business Daily)
Aug-18-25 09:55AM	Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade (Zacks) +5.65%
Aug-13-25 03:12AM	Mineralys Therapeutics Inc (MLYS) Q2 2025 Earnings Call Highlights: Pivotal Trial Success and ... (GuruFocus.com)
Aug-12-25 04:05PM	Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-25 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 (GlobeNewswire)
Jul-25-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? (Zacks)
Jul-01-25 02:42AM	Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat (Insider Monkey)
Jun-30-25 11:17AM	Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat (GlobeNewswire)
Jun-17-25 07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria (GlobeNewswire)
May-27-25 08:10AM	Mineralys announces late-breaking presentation of data from Launch-HTN trial (TipRanks)
May-26-25 09:15AM	Mineralys reports outcomes from trial of lorundrostat for hypertension (Clinical Trials Arena)
May-24-25 04:30AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) (GlobeNewswire)
May-22-25 08:50AM	Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going (Zacks)
May-20-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection (GlobeNewswire) +5.09%
May-19-25 12:00PM	Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy (Zacks)
May-13-25 07:08AM	Q1 2025 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-12-25 04:05PM	Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
May-05-25 04:05PM	Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 (GlobeNewswire) -7.49%
Apr-23-25 05:23PM	Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) (GlobeNewswire)
Mar-29-25 02:30PM	Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) (GlobeNewswire)
Mar-25-25 11:28AM	Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
08:00AM	Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET (GlobeNewswire)
Mar-18-25 07:58PM	Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) +8.51% +8.55%
04:01PM	Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire)
Mar-17-25 08:00AM	Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo (GlobeNewswire)
Mar-11-25 10:20PM	Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.32%
Mar-10-25 04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +42.21%
01:50PM	Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate (Benzinga)
12:57PM	Mineralyss stock soars as hypertension pill scores in two pivotal trials (Clinical Trials Arena)
07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension (GlobeNewswire)
06:30AM	Mineralys shares climb on study data for blood pressure drug (BioPharma Dive)
Mar-07-25 04:01PM	Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET (GlobeNewswire)
Feb-13-25 02:19AM	Q4 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:10AM	Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ... (GuruFocus.com)
Feb-12-25 07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.04%
Feb-05-25 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 (GlobeNewswire)
Feb-04-25 08:00AM	Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria (GlobeNewswire)
Jan-09-25 08:29AM	Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials (TipRanks)
Jan-08-25 08:00AM	Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension (GlobeNewswire) -13.71%
Nov-12-24 11:00PM	Mineralys Therapeutics Announces Q3 2024 Results and Updates (TipRanks) -10.32% -6.95%
10:12AM	Q3 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-11-24 04:05PM	Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +6.27%
Nov-05-24 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.66%
Nov-04-24 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 (GlobeNewswire)
Oct-30-24 08:00AM	Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)
Sep-25-24 08:00AM	Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Aug-28-24 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-24 04:05PM	Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -22.82%

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

M.P.H.Dr. Brian Taylor Slingsby M.D.

CFO & SecretaryMr. Adam Scott Levy

Chief Medical OfficerDr. David M. Rodman M.D.

Chief Legal OfficerMr. Jeffrey A. Munsie J.D.

Senior Vice President of CMCDr. Robert McKean Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rodman David Malcom	Chief Medical Officer	May 18 '26	Option Exercise	15.44	417	6,438	63,860	May 19 07:15 PM
Rodman David Malcom	Chief Medical Officer	May 18 '26	Sale	27.55	417	11,488	63,443	May 19 07:15 PM
Rodman David Malcom	Officer	May 18 '26	Proposed Sale	27.55	417	11,488		May 18 04:10 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Option Exercise	12.39	7,707	95,484	77,499	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Option Exercise	16.00	2,171	34,736	71,963	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Option Exercise	1.08	6,348	6,856	76,140	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Sale	28.58	14,056	401,789	63,443	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Sale	29.36	6,348	186,348	69,792	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Sale	29.71	2,171	64,500	69,792	May 13 09:42 PM
Rodman David Malcom	Officer	May 13 '26	Proposed Sale	28.58	14,056	401,790		May 13 04:11 PM
Rodman David Malcom	Officer	May 12 '26	Proposed Sale	29.36	6,348	186,348		May 12 05:05 PM
Rodman David Malcom	Officer	May 11 '26	Proposed Sale	29.71	2,171	64,500		May 11 04:27 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Option Exercise	15.44	416	6,423	70,208	Apr 21 06:59 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Sale	31.33	416	13,033	69,792	Apr 21 06:59 PM
Rodman David Malcom	Officer	Apr 17 '26	Proposed Sale	31.33	416	13,033		Apr 17 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Option Exercise	7.28	14,058	102,365	90,198	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Sale	26.54	14,058	373,087	76,140	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 15 '26	Sale	27.66	6,348	175,586	69,792	Apr 15 09:45 PM
Congleton Jon	Chief Executive Officer	Apr 13 '26	Sale	26.83	15,730	421,979	689,321	Apr 15 09:45 PM
Rodman David Malcom	Officer	Apr 15 '26	Proposed Sale	27.66	6,348	175,586		Apr 15 04:21 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Option Exercise	16.00	2,170	34,720	78,310	Apr 13 09:13 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Sale	27.38	2,170	59,415	76,140	Apr 13 09:13 PM
Congleton Jon	Officer	Apr 13 '26	Proposed Sale	26.83	15,730	421,980		Apr 13 04:22 PM
Rodman David Malcom	Officer	Apr 13 '26	Proposed Sale	26.54	14,058	373,087		Apr 13 04:18 PM
Rodman David Malcom	Officer	Apr 09 '26	Proposed Sale	27.38	2,170	59,415		Apr 09 04:24 PM
Congleton Jon	Chief Executive Officer	Mar 31 '26	Sale	26.27	75,000	1,970,522	705,051	Apr 02 06:54 PM
Karydas Daphne	Director	Mar 31 '26	Option Exercise	12.02	3,000	36,060	9,200	Apr 02 06:53 PM
Karydas Daphne	Director	Mar 31 '26	Sale	25.00	3,000	75,000	6,200	Apr 02 06:53 PM
Karydas Daphne	Officer	Mar 31 '26	Proposed Sale	25.00	3,000	75,000		Mar 31 04:18 PM
Congleton Jon	Officer	Mar 31 '26	Proposed Sale	26.27	75,000	1,970,521		Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '26	Buy	23.67	310,700	7,354,269	5,767,221	Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 30 '26	Buy	24.16	58,300	1,408,528	5,825,521	Mar 31 04:15 PM
Rodman David Malcom	Officer	Mar 17 '26	Proposed Sale	25.65	417	10,696		Mar 17 05:04 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Option Exercise	15.44	417	6,438	76,557	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Sale	25.65	417	10,696	76,140	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Option Exercise	12.39	7,709	95,508	90,198	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Option Exercise	1.08	6,348	6,856	88,837	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Sale	26.26	14,058	369,225	76,140	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Sale	27.37	6,348	173,748	82,489	Mar 16 05:20 PM
Rodman David Malcom	Officer	Mar 13 '26	Proposed Sale	26.26	14,058	369,225		Mar 13 04:50 PM
Rodman David Malcom	Officer	Mar 12 '26	Proposed Sale	27.37	6,348	173,748		Mar 12 04:13 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Option Exercise	16.00	2,171	34,736	84,660	Mar 10 05:48 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Sale	26.84	2,171	58,270	82,489	Mar 10 05:48 PM
Rodman David Malcom	Officer	Mar 09 '26	Proposed Sale	26.84	2,171	58,270		Mar 09 05:15 PM
Rodman David Malcom	Chief Medical Officer	Feb 17 '26	Option Exercise	15.44	417	6,438	44,506	Feb 17 06:56 PM
Rodman David Malcom	Chief Medical Officer	Feb 17 '26	Sale	27.59	417	11,505	44,089	Feb 17 06:56 PM
Rodman David Malcom	Officer	Feb 17 '26	Proposed Sale	27.59	417	11,505		Feb 17 04:05 PM
Rodman David Malcom	Chief Medical Officer	Feb 13 '26	Option Exercise	12.39	7,707	95,484	54,603	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '26	Option Exercise	1.08	6,349	6,857	56,786	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 13 '26	Sale	27.44	14,055	385,732	44,089	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '26	Sale	28.99	6,349	184,077	50,437	Feb 13 07:25 PM
Rodman David Malcom	Officer	Feb 13 '26	Proposed Sale	27.44	14,055	385,732		Feb 13 04:07 PM
Rodman David Malcom	Officer	Feb 12 '26	Proposed Sale	28.99	6,349	184,077		Feb 12 04:34 PM
Rodman David Malcom	Chief Medical Officer	Feb 09 '26	Option Exercise	16.00	2,171	34,736	52,608	Feb 11 06:58 PM
Rodman David Malcom	Chief Medical Officer	Feb 09 '26	Sale	30.21	2,171	65,586	50,437	Feb 11 06:58 PM
Rodman David Malcom	Officer	Feb 09 '26	Proposed Sale	30.21	2,171	65,586		Feb 09 04:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 20 '26	Option Exercise	15.44	416	6,423	50,853	Jan 20 08:33 PM
Rodman David Malcom	Chief Medical Officer	Jan 20 '26	Sale	32.10	416	13,354	50,437	Jan 20 08:33 PM
Rodman David Malcom	Officer	Jan 20 '26	Proposed Sale	32.10	416	13,354		Jan 20 04:26 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '26	Option Exercise	12.39	7,709	95,508	69,513	Jan 15 07:07 PM
Rodman David Malcom	Chief Medical Officer	Jan 14 '26	Sale	32.61	11,367	370,645	50,437	Jan 15 07:07 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '26	Sale	32.75	7,709	252,470	61,804	Jan 15 07:07 PM
Rodman David Malcom	Officer	Jan 14 '26	Proposed Sale	32.61	11,367	370,645		Jan 14 04:00 PM
Congleton Jon	Chief Executive Officer	Jan 12 '26	Sale	32.62	16,236	529,640	639,151	Jan 13 08:43 PM
Levy Adam Scott	CFO and Secretary	Jan 12 '26	Sale	32.14	10,758	345,723	8,638	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 09 '26	Option Exercise	16.00	2,170	34,720	63,974	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '26	Option Exercise	1.08	6,348	6,856	68,152	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '26	Sale	32.32	6,348	205,143	61,804	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 09 '26	Sale	33.27	2,170	72,196	61,804	Jan 13 08:43 PM
Rodman David Malcom	Officer	Jan 13 '26	Proposed Sale	32.75	7,709	252,470		Jan 13 04:10 PM
Rodman David Malcom	Officer	Jan 12 '26	Proposed Sale	32.32	6,348	205,143		Jan 12 04:24 PM
Levy Adam Scott	Officer	Jan 12 '26	Proposed Sale	32.14	10,758	345,723		Jan 12 04:23 PM
Congleton Jon	Officer	Jan 12 '26	Proposed Sale	32.62	16,236	529,640		Jan 12 04:23 PM
Rodman David Malcom	Officer	Jan 09 '26	Proposed Sale	33.27	2,170	72,196		Jan 09 04:23 PM
Rodman David Malcom	Chief Medical Officer	Jan 05 '26	Option Exercise	12.26	185,331	2,272,023	254,519	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 02 '26	Option Exercise	12.31	67,390	829,667	139,225	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 05 '26	Sale	35.02	192,715	6,749,109	61,804	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 02 '26	Sale	35.87	70,037	2,511,919	69,188	Jan 06 07:20 PM
Rodman David Malcom	Officer	Jan 02 '26	Proposed Sale	35.71	262,752	9,382,874		Jan 02 05:18 PM
Congleton Jon	Chief Executive Officer	Nov 21 '25	Option Exercise	0.54	24,082	13,004	655,387	Nov 24 05:07 PM
Slingsby Brian Taylor	Director	Nov 20 '25	Sale	43.35	1,000,000	43,350,000	7,903,838	Nov 21 06:07 PM
Catalys Pacific Fund, LP	Affiliate	Nov 20 '25	Proposed Sale	42.12	1,000,000	42,120,000		Nov 20 05:19 PM
Levy Adam Scott	CFO and Secretary	Nov 11 '25	Option Exercise	14.11	105,653	1,490,434	138,920	Nov 13 07:01 PM
Levy Adam Scott	CFO and Secretary	Nov 11 '25	Sale	44.88	119,524	5,363,716	19,396	Nov 13 07:01 PM
Congleton Jon	Chief Executive Officer	Nov 11 '25	Sale	45.44	200,000	9,088,499	631,305	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Option Exercise	10.20	15,000	153,000	15,000	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Sale	45.99	15,000	689,797	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 13 '25	Option Exercise	12.15	12,742	154,868	12,742	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 11 '25	Option Exercise	10.20	15,000	153,000	15,000	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 12 '25	Option Exercise	10.20	6,933	70,717	6,933	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 11 '25	Sale	43.98	15,000	659,706	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 13 '25	Sale	46.50	12,742	592,503	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 12 '25	Sale	46.72	6,933	323,886	0	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Proposed Sale	45.99	15,000	689,796		Nov 13 04:04 PM
Gold Alexander M	Director	Nov 12 '25	Proposed Sale	45.45	34,675	1,576,094		Nov 13 04:03 PM
Levy Adam Scott	Officer	Nov 11 '25	Proposed Sale	44.88	119,524	5,363,716		Nov 12 04:32 PM
Congleton Jon	Officer	Nov 11 '25	Proposed Sale	45.44	200,000	9,088,503		Nov 12 04:28 PM
Levy Adam Scott	CFO and Secretary	Oct 13 '25	Sale	42.01	10,758	451,984	116,865	Oct 15 07:04 PM
Congleton Jon	Chief Executive Officer	Oct 13 '25	Sale	42.67	15,100	644,327	831,305	Oct 15 07:04 PM
Rodman David Malcom	Chief Medical Officer	Oct 15 '25	Sale	43.01	10,369	445,982	71,155	Oct 15 07:04 PM

Open in Screener

NGNE

Neurogene Inc

Jun 05 • 04:00PM ET

26.49

-0.99 -3.60 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: INCY KYMR NUVL BMRN RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VXF IWN KOMP IBB FESM VTWO IWC AVSC

Index	RUT	P/E	-	EPS (ttm)	-5.02	Insider Own	20.70%	Shs Outstand	15.62M	Perf Week	-6.53%
Market Cap	418.59M	Forward P/E	-	EPS next Y	-5.53	Insider Trans	-0.97%	Shs Float	12.53M	Perf Month	-18.06%
Enterprise Value	184.54M	PEG	-	EPS next Q	-1.43	Inst Own	96.75%	Short Float	28.76%	Perf Quarter	19.49%
Income	-98.64M	P/S	-	EPS this Y	-31.47%	Inst Trans	1.97%	Short Ratio	24.04	Perf Half Y	31.66%
Sales	0.00M	P/B	1.74	EPS next Y	0.87%	ROA	-34.10%	Short Interest	3.60M	Perf YTD	28.59%
Book/sh	15.23	P/C	1.72	EPS next 5Y	-4.16%	ROE	-37.25%	52W High	37.27 -28.92%	Perf Year	15.58%
Cash/sh	15.39	P/FCF	-	EPS past 3/5Y	0.52% -45.84%	ROIC	-40.45%	52W Low	14.65 80.82%	Perf 3Y	63.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.01% 6.83%	Perf 5Y	-86.57%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-7.33%	Oper. Margin	-	ATR (14)	1.81	Perf 10Y	-83.55%
Dividend Ex-Date	-	Quick Ratio	13.07	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	46.04	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.07	EPS Q/Q	-28.57%	SMA20	-6.68%	Beta	1.71	Target Price	78.75
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	1.59%	Rel Volume	0.45	Prev Close	27.48
Employees	131	LT Debt/Eq	0.03	Earnings	May 12 AMC	SMA200	16.73%	Avg Volume	149.91K	Price	26.49
IPO	Mar 07, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.23% -	Trades		Volume	67,356	Change	-3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-26	Initiated	Rodman & Renshaw	Buy	$70
Jun-17-25	Initiated	Craig Hallum	Buy	$50
May-16-25	Downgrade	Robert W. Baird	Outperform → Neutral	$24
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$65
Jun-11-24	Initiated	Robert W. Baird	Outperform	$54
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

Jun-02-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.08%
May-12-26 04:25PM	Neurogene: Q1 Earnings Snapshot (Associated Press)
04:05PM	Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates (Business Wire)
06:00AM	Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy (Business Wire)
May-06-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.71%
07:30AM	Loading…
Apr-28-26 07:30AM	Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy (Business Wire)
Apr-20-26 07:30AM	Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors (Business Wire)
Apr-08-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-26 07:46AM	Neurogene: Q4 Earnings Snapshot (Associated Press Finance) +7.95%
07:30AM	Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates (Business Wire)
Mar-11-26 07:30AM	Neurogene to Participate in Stifel 2026 Virtual CNS Forum (Business Wire)
Mar-03-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.03% +8.73%
Feb-27-26 09:50AM	Block upgraded, Duolingo downgraded: Wall Street's top analyst calls (The Fly) +19.36%
08:06AM	Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy (Benzinga)
07:59AM	Here Are Fridays Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More (24/7 Wall St.)
07:40AM	Loading…
07:40AM	Why Did NGNE Stock Surge 25% In Pre-Market Today? (New feeds test provider finance)
Feb-26-26 04:01PM	Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Feb-14-26 09:05AM	Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit (MarketBeat)
Feb-05-26 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Feb-04-26 04:01PM	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-26 07:00AM	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome (Business Wire)
Jan-05-26 07:30AM	Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -8.58%
Dec-04-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.17%
Nov-13-25 05:21PM	Neurogene: Q3 Earnings Snapshot (Associated Press Finance) -14.77% -14.04%
05:10PM	Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
Nov-12-25 04:01PM	Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome (Business Wire)
Nov-06-25 07:30AM	Neurogene Announces First Participant Dosed in Embolden Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Nov-05-25 04:01PM	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.83%
Oct-09-25 07:00AM	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden Registrational Trial in Q4 2025 (Business Wire) +22.18%
Oct-08-25 07:30AM	Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference (Business Wire) +10.06%
04:01PM	Loading…
Oct-03-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.48%
Sep-05-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com)
Aug-11-25 05:55PM	Neurogene: Q2 Earnings Snapshot (Associated Press Finance) -5.55%
04:10PM	Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
Aug-08-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:01PM	Neurogene Announces Registrational Trial Design for Embolden Study of NGN-401 Gene Therapy for Rett Syndrome (Business Wire) -7.49% +28.36%
Jun-18-25 09:16AM	Craig-Hallum bullish on Neurogene, initiates with a Buy (TipRanks)
Jun-06-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.80%
May-26-25 11:15AM	Short Report: Bears bite into Krispy Kreme after another weak earnings report (TipRanks)
May-16-25 07:00AM	Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV (Business Wire) -7.12%
May-09-25 07:30AM	Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
May-08-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.23%
Apr-28-25 05:00PM	Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting (Business Wire) -5.91% -10.14%
Apr-02-25 04:01PM	Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome (Business Wire) +8.34% -7.55%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -17.55%
Mar-24-25 04:10PM	Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates (Business Wire)
Feb-24-25 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Nov-18-24 05:25PM	Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire) -42.58% -13.07%
04:14PM	How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week (Investor's Business Daily)
09:48AM	Neurogene Down 36% Extends Losses After Side Effect Derails Its Rett Syndrome Drug (Investor's Business Daily)
06:45AM	Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-12-24 04:10PM	Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal (Investor's Business Daily) -44.08%
10:18AM	Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect (Investor's Business Daily)
06:58AM	Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data (GuruFocus.com)
Nov-11-24 04:01PM	Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-05-24 07:54AM	Neurogene Secures $200M for Genetic Therapy Development (TipRanks)
Nov-04-24 07:30AM	Neurogene Announces Oversubscribed $200 Million Private Placement (Business Wire) +43.26%
Oct-21-24 07:30AM	Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Aug-09-24 02:52PM	NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 (InvestorPlace)
07:30AM	Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
Aug-07-24 07:30AM	Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome (Business Wire)
Jul-02-24 07:30AM	Neurogene to Participate in BMO Genetic Medicines Summit (Business Wire) -5.32%
Jul-01-24 07:30AM	Neurogene Announces Addition to Russell 3000 Index (Business Wire) +11.62%
Jun-19-24 09:23AM	Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation (Insider Monkey)
Jun-18-24 09:26AM	Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire) -24.20%
Jun-05-24 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Jun-03-24 07:30AM	Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program (Business Wire)
May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire) +20.00%
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

FounderDr. Rachel L. McMinn Ph.D.

PresidentMs. Christine Mikail Cvijic J.D.

Chief Medical OfficerDr. Julie Jordan M.D.

Chief Scientific OfficerDr. Stuart Cobb Ph.D.

L.L.M.Ms. Donna M. Cochener-Metcalfe J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cvijic Christine Mikail	President and CFO	May 06 '26	Sale	31.25	9,600	300,043	93,640	May 08 11:51 AM
Christine Cvijic	Officer	May 06 '26	Proposed Sale	28.94	14,400	416,736		May 06 04:14 PM
Cvijic Christine Mikail	President and CFO	Mar 26 '26	Sale	21.62	2,558	55,316	103,240	Mar 30 05:38 PM
McMinn Rachel	Chief Executive Officer	Mar 26 '26	Sale	22.07	3,352	73,995	1,344,307	Mar 30 05:38 PM
Jordan Julie	Chief Medical Officer	Mar 26 '26	Sale	21.89	828	18,128	12,472	Mar 30 05:38 PM
Cobb Stuart	Chief Scientific Officer	Mar 13 '26	Sale	20.81	6,797	141,446	30,497	Mar 17 06:01 PM
Cvijic Christine Mikail	President and CFO	Mar 13 '26	Sale	20.81	4,045	84,176	105,798	Mar 17 06:01 PM
STUART COBB	Officer	Mar 13 '26	Proposed Sale	22.30	6,797	151,573		Mar 13 04:20 PM
Cvijic Christine Mikail	President and CFO	Feb 27 '26	Sale	25.11	4,800	120,526	109,843	Mar 03 05:03 PM
Christine Cvijic	Officer	Feb 27 '26	Proposed Sale	19.68	9,600	188,928		Feb 27 04:51 PM

MLYS

Mineralys Therapeutics Inc

NGNE

Neurogene Inc

Upgrade your Finviz experience